Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 419)

CONTINUING CONNECTED TRANSACTIONS
2026 SHARED SERVICES AGREEMENTS

THE 2026 SHARED SERVICES AGREEMENTS

On 8 April 2026 (after trading hours), Shaanxi Yizhinuo and Suzhou Yizhinuo entered into the 2026 Shared Services Agreements with Xian Medical Chain, pursuant to which, among others, (i) the 2026 Shared Services Agreements shall replace the 2025 Flexible Staffing Services Agreements with effect from the date of the 2026 Shared Services Agreements, and the 2025 Flexible Staffing Services Agreements shall be terminated accordingly; and (ii) Shaanxi Yizhinuo and Suzhou Yizhinuo agreed to appoint Xian Medical Chain as the service provider for the provision of shared services solutions to support the Group's digitized operation services in the healthcare industry with a term commencing from 8 April 2026 to 31 December 2028.

LISTING RULES IMPLICATIONS

(i) the 2025 Flexible Staffing Services Agreements

Reference is made to the Previous Announcement. On 27 February 2026, the Company was informed by Ms. SHANG that Xian Medical Chain has become an associate of Ms. SHANG, and hence a connected person of the Company at subsidiary level under Chapter 14A of the Listing Rules. Accordingly, the Previous Transactions during the Relevant Period under the 2025 Flexible Staffing Services Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

On 9 March 2026, the Company published the Previous Announcement in relation to the Previous Transactions under the 2025 Flexible Staffing Services Agreements pursuant to Rule 14A.60 of the Listing Rules. Following further analysis of the relevant Listing Rules, the Company wishes to clarify that the 2025 Flexible Staffing Services Agreements and the transactions contemplated thereunder should not be subject to Rule 14A.60 of the Listing Rules, as the terms thereunder are not fixed, which is one of the requirements stipulated under Rule 14A.60 of the Listing Rules.

As (i) the aggregate transaction amount of the Previous Transactions has exceeded HK$3,000,000 on 28 February 2026; and (ii) the highest applicable percentage ratio (as defined in the Listing Rules) in respect of the Previous Transactions under the 2025 Flexible Staffing Services Agreements during the Relevant Period has exceeded 1% starting from 2 March 2026, the Previous Transactions no longer qualify for full exemption under Rule 14A.76(1)(c) and Rule 14A.76(1)(b) of the Listing Rules, respectively. Accordingly, the 2025 Flexible Staffing Services Agreements should have been, but were not, announced on 2 March 2026 in accordance with Rule 14A.35 of the Listing Rules. The non-timely announcement of the 2025 Flexible Staffing Services Agreements was due to inadvertent misinterpretation of the requirements under Rule 14A.60 of the Listing Rules.

Since (i) Xian Medical Chain is regarded as a connected person of the Company at subsidiary level; (ii) the Board (including all the independent non-executive Directors) has approved the Previous Transactions; and (iii) the independent non-executive Directors have confirmed that the terms of the 2025 Flexible Staffing Services Agreements (including the Previous Transactions) are fair and reasonable, on normal commercial terms or better and in the interests of the Company and the Shareholders as a whole, the Previous Transactions contemplated under the 2025 Flexible Staffing Services Agreements are subject to the reporting, announcement and annual review requirements but are exempt from the circular, independent financial advice and shareholders' approval requirements pursuant to Rule 14A.101 of the Listing Rules.

(ii) the 2026 Shared Services Agreements

As at the date of this announcement, Xian Medical Chain is an associate of Ms. SHANG and hence a connected person of the Company at subsidiary level under Chapter 14A of the Listing Rules. Accordingly, the entering into of the 2026 Shared Services Agreements and the transactions contemplated thereunder constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Since (i) Xian Medical Chain is regarded as a connected person of the Company at subsidiary level; (ii) the Board (including all the independent non-executive Directors) has approved the transactions contemplated under the 2026 Shared Services Agreements; and (iii) the independent non-executive Directors have confirmed that the terms of the 2026 Shared Services Agreements are fair and reasonable, on normal commercial terms or better and in the interests of the Company and the Shareholders as a whole, the transactions contemplated under the 2026 Shared Services Agreements are subject to the reporting, announcement and annual review requirements but are exempt from the circular, independent financial advice and shareholders' approval requirements pursuant to Rule 14A.101 of the Listing Rules.

GENERAL

The Board confirms that none of the Directors has a material interest in the transactions contemplated under the 2026 Shared Services Agreements and hence no Director is required to abstain from voting on the resolutions of the Board approving the transactions contemplated under the 2026 Shared Services Agreements.

INTRODUCTION

On 8 April 2026 (after trading hours), Shaanxi Yizhinuo and Suzhou Yizhinuo entered into the 2026 Shared Services Agreements with Xian Medical Chain, pursuant to which, among others, (i) the 2026 Shared Services Agreements shall replace the 2025 Flexible Staffing Services Agreements with effect from the date of the 2026 Shared Services Agreements, and the 2025 Flexible Staffing Services Agreements shall be terminated accordingly; and (ii) Shaanxi Yizhinuo and Suzhou Yizhinuo agreed to appoint Xian Medical Chain as the service provider for the provision of shared services solutions to support the Group's digitized operation services in the healthcare industry with a term commencing from 8 April 2026 to 31 December 2028.

THE 2026 SHARED SERVICES AGREEMENTS

The terms of each of the 2026 Shared Services Agreements are identical in all material respects, except for the signing party. Details of the 2026 Shared Services Agreements are set out below.

Date: 8 April 2026 *(after trading hours)*

Parties: *The 2026 Shared Services Agreement I*

(1) Shaanxi Yizhinuo; and

(2) Xian Medical Chain.

The 2026 Shared Services Agreement II

(1) Suzhou Yizhinuo; and

(2) Xian Medical Chain.

Term: 8 April 2026 to 31 December 2028 (both days inclusive)

Subject matter: Shaanxi Yizhinuo and Suzhou Yizhinuo agreed to appoint Xian Medical Chain as the service provider for the provision of shared services solutions to support the Group's digitized operation services in the healthcare industry.

The shared services solutions primarily involve Xian Medical Chain's handling of processes such as worker's engagement, contract management, settlement of remuneration and payment processing with number of workers ("**Workers**") identified, decided and required by Group from time to time to support the Group's digitized operation services in the healthcare industry.

Service fees and pricing mechanism: The fees payable by Shaanxi Yizhinuo and Suzhou Yizhinuo to Xian Medical Chain comprise:

(i) the labour remuneration (the "**Labour Remuneration**") which is equivalent to the actual remuneration payable to the Workers (being individuals including but not limited to medical and healthcare practitioners identified, decided and required by the Group from time to time), calculated on a cost basis. The Labour Remuneration for each Worker shall be determined by the Group with reference to, among others, the then prevailing market rate and conditions, as well as the individual's background, experience, qualifications and duties; and

(ii) a service fee (the "**Service Fee**"), determined on a tiered basis as follows:

(a) if the total Labour Remuneration payable amount under the 2026 Shared Services Agreements in a calendar month is equal to or less than RMB10,000,000, a Service Fee at the rate of 6.80% of the total Labour Remuneration; or

(b) if the total Labour Remuneration payable under the 2026 Shared Services Agreements in a calendar month exceeds RMB10,000,000, a Service Fee at the rate of 5.90% of the total Labour Remuneration.

The above Service Fee rates are determined by the Group with reference to (i) the prevailing market rate and the requirements of the relevant services (e.g. the number of Workers required in each project, the nature and scope of the services provided, the anticipated transaction amount etc.); (ii) the similar service fee rate charged by another independent service provider for similar services (which is currently one of the largest service providers in the PRC) to the Group; and (iii) at least two quotations obtained by the Group from independent third parties for comparable services (which include one of the largest service providers in the PRC). The amount and/or method of calculation of the Service Fee charged by Xian Medical Chain to the Group shall be on normal commercial terms and on terms no less favourable to the Group than those offered by other independent service providers for similar services.

The parties shall review and discuss the Service Fee rates on a quarterly basis, and if needed, may agree to adjust the Service Fee rates which shall be determined based on arm's length negotiations with reference to the aforesaid factors.

The total amount of the Labour Remuneration and the Service Fee shall be payable by Shaanxi Yizhinuo and Suzhou Yizhinuo to Xian Medical Chain within three days upon the receipt of the payment notification from Xian Medical Chain.

Historical transaction amounts

Set out below are the aggregate transaction amounts between (a) Shaanxi Yizhinuo and Suzhou Yizhinuo (in aggregate); and (b) Xian Medical Chain under the 2025 Flexible Staffing Services Agreements for (i) the period from 18 November 2025 to 31 December 2025; (ii) the period from 1 January 2026 to 26 February 2026; and (iii) the Relevant Period:

	For the period from 18 November 2025 to 31 December 2025	**For the period from 1 January 2026 to 26 February 2026**	**For the Relevant Period**
	RMB'000	***RMB'000***	***RMB'000***
	(unaudited)	*(unaudited)*	*(unaudited)*
The aggregate transaction amounts under the 2025 Flexible Staffing Services Agreements	14,143	41,370	37,243*(Note)*

Note: for illustrative purpose only, the annualised amount calculated based on the historical transaction amount recorded by the Group during the Relevant Period (excluding certain dates of the public holidays period, in which there was no transaction incurred under the 2025 Flexible Staffing Services Agreements) is approximately RMB378 million. Such figure does not purport the actual transaction amount for the year ending 31 December 2026.

Proposed annual caps

The proposed annual caps for the transactions contemplated under the 2026 Shared Services Agreements are set out below:

	From 8 April 2026 to 31 December 2026	**From 1 January 2027 to 31 December 2027**	**From 1 January 2028 to 31 December 2028**
	RMB'000	***RMB'000***	***RMB'000***
Proposed annual caps under the 2026 Shared Services Agreements	360,000	400,000	440,000

Despite the amount of the proposed annual caps being substantial relative with the Group's historical revenue, the Directors are of the view that, in addition to the internal control measures in place to safeguard the interests of the Company and its Shareholders, there is no undue reliance on Xian Medical Chain for the following reasons:

(i) subject to the actual terms offered by the service providers at the relevant time (which should be on normal commercial terms or better), the Group's allocation of sourcing its shared services solutions may reach 50% or more from connected parties (including Xian Medical Chain) during the three years ending 31 December 2028;

(ii) the Group has established and will continue to maintain close business relationships with at least three independent service providers for similar shared services solutions (which include one of the largest service providers in the PRC);

(iii) the shared services solutions providers are readily available in the market, and the Group would be able to easily procure comparable services from other independent service providers to replace Xian Medical Chain, as and when required;

(iv) the proposed annual caps represent the maximum limit on the potential transaction amounts between the Group and Xian Medical Chain. The 2026 Shared Services Agreements and the transactions contemplated thereunder are not exclusive in nature. There is also no commitment nor obligation on either party to the 2026 Shared Services Agreements. The 2026 Shared Services Agreements merely provide the Group with an additional option for sourcing the relevant services when needed. The Group has its full discretion to negotiate with Independent Third Parties and select service provider offering comparable or better terms; and

(v) having considered the above, the Group is not dependent on Xian Medical Chain for the provision of the shared services solutions in its business operations. Accordingly, any potential change in the relationship between the Group and Xian Medical Chain is unlikely to result in a material adverse impact on the Group's business operations.

Basis of determination of annual caps

In determining the proposed annual caps for the transactions contemplated under the 2026 Shared Services Agreements, the Company has taken into account the following factors, including:

(i) the Group's historical demand and utilisation of shared services solutions (such as flexible staffing solutions) provided by independent service provider(s) to support its operations, which ranged from approximately RMB408 million to RMB820 million during the past three years ended 31 December 2025;

(ii) the historical transaction amounts between (a) Shaanxi Yizhinuo and Suzhou Yizhinuo (in aggregate); and (b) Xian Medical Chain under the 2025 Flexible Staffing Services Agreements;

(iii) the estimated future demand for the shared services solutions over the three years ending 31 December 2028, having regard to the estimated scale of operations, and market demand trends, as well as the continuous development of the Group's digitized operation services in healthcare industry; and

(iv) a reasonable buffer of approximately 10% to cater for potential business growth and any unanticipated fluctuations in the demand for the shared services solutions.

INTERNAL CONTROL

The Group has adopted the following measures to monitor and govern the transactions under the 2026 Shared Services Agreements:

(a) the company secretarial department of the Company (the **"Company Secretarial Department"**) is primarily responsible for reviewing and monitoring the continuing connected transactions of the Company to ensure that the annual caps of the relevant continuing connected transactions are not exceeded and that the continuing connected transactions have been conducted in accordance with the pricing policies or mechanisms under the agreements relating to such continuing connected transactions. When the accumulated amounts exceed 50% of the approved annual caps of continuing connected transactions of the Company, the Company Secretarial Department will make a specific notification to the Chief Financial Officer of the Company. The Chief Financial Officer of the Company will in turn report to the audit committee of the Company and a re-assessment will be conducted. If it is determined after such re-assessment that the annual cap of continuing connected transactions of the Company may be exceeded, the Company would initiate the procedures for a board meeting and/or shareholders' meeting (as and when required) to increase the annual cap as soon as practicable;

(b) In addition to the internal control mentioned in paragraph (a) above, on a half-yearly basis, the Chief Financial Officer also provides a confirmation and relevant supporting evidence to the audit committee of the Company that the continuing connected transactions of the Company which are subject to the annual review and disclosure requirements under the Listing Rules have been entered into (i) in the ordinary and usual course of business of the Group; (ii) on normal commercial terms or better (having such meaning as defined in the Listing Rules) and no less favourable to the Group than those offered by or to other Independent Third Parties; and (iii) in accordance with the relevant agreements governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole; and the audit committee of the Company will be in a position to check that the Group's internal control procedures applicable to continuing connected transactions are adequate and effective to ensure that such transactions were so conducted;

(c) the independent non-executive Directors will conduct annual review on the continuing connected transactions to confirm whether the transactions have been entered into (i) in the ordinary and usual course of business of the Group; (ii) on normal commercial terms or better; and (iii) in accordance with the agreement governing them on terms that are fair and reasonable and in the interests of the Shareholders as a whole; and

(d) the auditors of the Company will conduct annual review on the continuing connected transactions of the Group to confirm that the continuing connected transactions (i) have been approved by the Board; (ii) were in all material respects, in accordance with the pricing policies of the Group; and (iii) were entered into, in all material respects, in accordance with the relevant agreement governing them.

REASONS FOR AND BENEFITS OF THE 2026 SHARED SERVICES AGREEMENTS

The principal activity of the Company is investment holding. The Group is principally engaged in (i) digitized operation services in healthcare industry; and (ii) entertainment and media business.

Being part of its principal businesses, the Group operates "Echartnow" through among others, its subsidiaries namely Shaanxi Yizhinuo and Suzhou Yizhinuo. "Echartnow" provides pharmaceutical companies with digitized operation services, such as the provision of marketing, medical conferences, medical science popularization and digitized promotion services to customers in the pharmaceutical

industry based on online ecological platform.

In order to fulfil the needs of pharmaceutical companies, the Group implements numerous digitized operation projects and missions (such as organization of academic conferences, production and promotion of medical science popularization content, production and publication of professional articles and videos in medical and healthcare industry, etc.) from time to time. Implementation and execution of such projects and missions would generate floating demand of necessitate additional manpower, especially for medical and healthcare practitioners, for a short-to-medium term project based periods. Instead of employing full-time medical and healthcare practitioners, the 2026 Shared Services Agreements enable the Group to optimize its human resources allocation by outsourcing required positions to external service providers based on its floating business needs. This arrangement efficiently addresses fluctuations in manpower demand arising from seasonal, phased, or cyclical factors. It also helps to reduce the Group's human resource and administrative burden as Xian Medical Chain will handle key administrative matters such as contract management, settlement of remuneration, payment processing and related matters with the Workers.

The Directors (including the independent non-executive Directors), are of the view that the 2026 Shared Services Agreements and the transactions contemplated thereunder have been entered into on normal commercial terms or better, in the ordinary and usual course of business of the Group, and that the terms and proposed annual caps of the 2026 Shared Services Agreements are fair and reasonable and in the interests of the Company and the Shareholders taken as a whole.

INFORMATION OF THE PARTIES

Shaanxi Yizhinuo and Suzhou Yizhinuo are the indirect subsidiaries of the Company and are principally engaged in the provision of digitized operation services in healthcare industry in the PRC.

Xian Medical Chain is a company established in the PRC with limited liability. It is (i) 51.0% owned by Xian Wanwusheng, (ii) approximately 40.8% owned by Xian Romantic Starting Point Enterprise Management Partnership (Limited Partnership)*(西安浪漫起點企業管理合夥企業(有限合夥)(**"Xian Romantic"**) and (iii) approximately 8.2% owned by Ms. Shanghua (尚華).

Xian Wanwusheng is (i) approximately 62.17% owned by Xian Lihe Tongdao Enterprise Management Partnership (Limited Partnership)* (西安力合同道企業管理合夥企業(有限合夥)) (**"Xian Lihe"**), (ii) approximately 19.13% owned by Zhangjiagang Lihe Tongdao Enterprise Management Partnership (Limited Partnership)* (張家港力合同道企業管理合夥企業(有限合夥) (**"Zhangjiagang Lihe"**), (iii) approximately 14.35% owned by Ms. SHANG and (iv) approximately 4.35% owned by Xian Gaotou Qiwei Future Investment Fund Partnership (Limited Partnership)* (西安高投啟微未來投資基金合夥企業(有限合夥) (**"Xian Gaotou"**), which is a state-owned entity.

Xian Lihe is (i) 73.80% owned by Ms. SHANG, (ii) approximately 15.38% owned by Ms. CHEN Cuie (陳翠娥), (iii) approximately 7.69% owned by Mr. MENG Qingyu (孟慶宇), (iv) approximately 3.08% owned by Mr. SHI Weifei (石衛飛) and (v) approximately 0.05% owned by Nuohe Tongdao (Hainan) Investment Co., Ltd.* (諾和同道(海南)投資有限公司) (**"Nuohe"**).

Zhangjiagang Lihe is 99% owned by Ms. SHANG and 1% owned by Nuohe.

Nuohe is 99% owned by Ms. SHANG and 1% owned by Ms. Liu Ying (劉瑩).

Xian Romantic is 99% owned by Mr. ZHANG Jie (張杰) and 1% owned by Mr. ZHANG Weiguang (張衛廣).

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, each of Ms. Shanghua, Xian Romantic, Mr. ZHANG Jie, Mr. ZHANG Weiguang, Ms. CHEN Cuie, Mr. MENG Qingyu, Mr. SHI Weifei, Xian Gaotou and Ms. Liu Ying is an Independent Third Party.

LISTING RULES IMPLICATIONS

(i) the 2025 Flexible Staffing Services Agreements

Reference is made to the Previous Announcement. On 27 February 2026, the Company was informed by Ms. SHANG that Xian Medical Chain has become an associate of Ms. SHANG, and hence a connected person of the Company at subsidiary level under Chapter 14A of the Listing Rules. Accordingly, the Previous Transactions during the Relevant Period under the 2025 Flexible Staffing Services Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

On 9 March 2026, the Company published the Previous Announcement in relation to the Previous Transactions under the 2025 Flexible Staffing Services Agreements pursuant to Rule 14A.60 of the Listing Rules. Following further analysis of the relevant Listing Rules, the Company wishes to clarify that the 2025 Flexible Staffing Services Agreements and the transactions contemplated thereunder should not be subject to Rule 14A.60 of the Listing Rules, as the terms thereunder are not fixed, which is one of the requirements stipulated under Rule 14A.60 of the Listing Rules.

As (i) the aggregate transaction amount of the Previous Transactions has exceeded HK$3,000,000 on 28 February 2026; and (ii) the highest applicable percentage ratio (as defined in the Listing Rules) in respect of the Previous Transactions under the 2025 Flexible Staffing Services Agreements during the Relevant Period has exceeded 1% starting from 2 March 2026, the Previous Transactions no longer qualify for full exemption under Rule 14A.76(1)(c) and Rule 14A.76(1)(b) of the Listing Rules, respectively. Accordingly, the 2025 Flexible Staffing Services Agreements should have been, but were not, announced on 2 March 2026 in accordance with Rule 14A.35 of the Listing Rules. The non-timely announcement of the 2025 Flexible Staffing Services Agreements was due to inadvertent misinterpretation of the requirements under Rule 14A.60 of the Listing Rules.

Since (i) Xian Medical Chain is regarded as a connected person of the Company at subsidiary level; (ii) the Board (including all the independent non-executive Directors) has approved the Previous Transactions; and (iii) the independent non-executive Directors have confirmed that the terms of the 2025 Flexible Staffing Services Agreements (including the Previous Transactions) are fair and reasonable, on normal commercial terms or better and in the interests of the Company and the Shareholders as a whole, the Previous Transactions contemplated under the 2025 Flexible Staffing Services Agreements are subject to the reporting, announcement and annual review requirements but are exempt from the circular, independent financial advice and shareholders' approval requirements pursuant to Rule 14A.101 of the Listing Rules.

(ii) the 2026 Shared Services Agreements

As at the date of this announcement, Xian Medical Chain is an associate of Ms. SHANG and hence a connected person of the Company at subsidiary level under Chapter 14A of the Listing Rules. Accordingly, the entering into of the 2026 Shared Services Agreements and the transactions contemplated thereunder constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

Since (i) Xian Medical Chain is regarded as a connected person of the Company at subsidiary level; (ii) the Board (including all the independent non-executive Directors) has approved the transactions contemplated under the 2026 Shared Services Agreements; and (iii) the independent non-executive Directors have confirmed that the terms of the 2026 Shared Services Agreements are fair and reasonable, on normal commercial terms or better and in the interests of the Company and the Shareholders as a whole, the transactions contemplated under the 2026 Shared Services Agreements are subject to the reporting, announcement and annual review requirements but are exempt from the circular, independent financial advice and shareholders' approval requirements pursuant to Rule 14A.101 of the Listing Rules.

REMEDIAL MEASURES

The Group has taken several remedial measures to avoid any recurrence of similar non-compliance in the future, including but not limited to:

(i) internal training materials have been distributed in late March 2026 to all the Directors and senior management/relevant personnel of the Company and its subsidiaries to reinforce their knowledge on the requirements under Chapter 14A of the Listing Rules;

(ii) a list of connected persons will be updated on a half-yearly basis and circulated to each member of the Group to assist them identifying which counterparty is a connected person of the Group;

(iii) the relevant departments of each member of the Group (such as the finance team and/or the legal team) will be required to conduct routine checks (in addition to pre-transaction checks) on a half-yearly basis, confirm the identity and ultimate beneficial ownership of transaction counterparties, and escalate any identified connected transaction to the Company Secretarial Department in a timely manner in order to ascertain whether there will be any connected transaction implication under Chapter 14A of the Listing Rules;

(iv) seeking legal advice and other professional advice from time to time to ensure compliance with the Listing Rules.

GENERAL

The Board confirms that none of the Directors has a material interest in the transactions contemplated under the 2026 Shared Services Agreements and hence no Director is required to abstain from voting on the resolutions of the Board approving the transactions contemplated under the 2026 Shared Services Agreements.

DEFINITIONS

In this announcement, the following expressions shall have the meanings set out below unless the context requires otherwise:

"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Board"	board of the Directors
"Company"	Hony Media Group, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange

"connected person(s)"	has the meaning as ascribed in the Listing Rules
"Director(s)"	the director(s) of the Company
"2025 Flexible Staffing Services Agreement I"	the services agreement entered into between Shaanxi Yizhinuo and Xian Medical Chain on 18 November 2025 in relation to the provision of flexible staffing solutions by Xian Medical Chain to Shaanxi Yizhinuo (as amended by the Supplemental Agreement I)
"2025 Flexible Staffing Services Agreement II"	the services agreement entered into between Suzhou Yizhinuo and Xian Medical Chain on 18 November 2025 in relation to the provision of flexible staffing solutions by Xian Medical Chain to Suzhou Yizhinuo (as amended by the Supplemental Agreement II)
"2025 Flexible Staffing Services Agreements"	collectively, the 2025 Flexible Staffing Services Agreement I and the 2025 Flexible Staffing Services Agreement II
"2026 Shared Services Agreement I"	the services agreement entered into between Shaanxi Yizhinuo and Xian Medical Chain on 8 April 2026 in relation to the provision of shared services solutions (equivalent to the flexible staffing solutions as described in 2025 Flexible Staffing Services Agreement I) by Xian Medical Chain to Shaanxi Yizhinuo
"2026 Shared Services Agreement II"	the services agreement entered into between Suzhou Yizhinuo and Xian Medical Chain on 8 April 2026 in relation to the provision of shared services solutions (equivalent to the flexible staffing solutions as described in 2025 Flexible Staffing Services Agreement II) by Xian Medical Chain to Suzhou Yizhinuo
"2026 Shared Services Agreements"	collectively, the 2026 Shared Services Agreement I and the 2026 Shared Services Agreement II
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Independent Third Party(ies)"	party(ies) which is/are independent of the Group and the connected persons of the Company
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Ms. SHANG"	Ms. SHANG Jing, a director of both Shaanxi Yizhinuo and Suzhou Yizhinuo

"PRC"	the People's Republic of China and, for the purpose of this announcement, excluding Hong Kong, Macao Special Administrative Region of the People's Republic of China and Taiwan
"Previous Announcement"	the announcement of the Company dated 9 March 2026 in relation to the continuing transactions under the 2025 Flexible Staffing Services Agreements
"Previous Transactions"	the transactions during the Relevant Period under the 2025 Flexible Staffing Services Agreements
"Relevant Period"	the period from 27 February 2026 up to (but excluding) the date of the 2026 Shared Services Agreements
"Shaanxi Yizhinuo"	Shaanxi Yizhinuo Information Technology Co., Ltd.* (陝西醫智諾信息科技有限公司), a company established in the PRC with limited liability and being an indirect subsidiary of the Company
"Share(s)"	ordinary share(s) of HK$0.20 each in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Supplemental Agreement I"	the supplemental agreement entered into between Shaanxi Yizhinuo and Xian Medical Chain on 13 February 2026 to revise the Service Fee rate under the 2025 Flexible Staffing Services Agreement I from a flat rate of 6.20%, to a tiered basis as follows: (i) 5.90% (if the total Labour Remuneration payable under the 2025 Flexible Staffing Services Agreements in a calendar month exceeds RMB10,000,000); or (ii) 6.80% (if the total Labour Remuneration payable amount under the 2025 Flexible Staffing Services Agreements in a calendar month is equal to or less than RMB10,000,000)
"Supplemental Agreement II"	the supplemental agreement entered into between Suzhou Yizhinuo and Xian Medical Chain on 13 February 2026 to revise the Service Fee rate under the 2025 Flexible Staffing Services Agreement II from a flat rate of 6.20%, to a tiered basis as follows: (i) 5.90% (if the total Labour Remuneration payable under the 2025 Flexible Staffing Services Agreements in a calendar month exceeds RMB10,000,000); or (ii) 6.80% (if the total Labour Remuneration payable amount under the 2025 Flexible Staffing Services Agreements in a calendar month is equal to or less than RMB10,000,000)

"Suzhou Yizhinuo"	Yizhinuo Technology (Suzhou) Co., Ltd.* (醫智諾科技(蘇州)有限公司), a company established in the PRC with limited liability and being an indirect subsidiary of the Company
"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"Xian Medical Chain"	Xian Medical Chain Information Technology Co., Ltd.* (西安醫鏈通信息技術有限公司), a company established in the PRC with limited liability and being the service provider under the 2026 Shared Services Agreements
"Xian Wanwusheng"	Xian Wanwusheng Data Technology Co., Ltd.* (西安萬物生數據科技有限公司), a company established in the PRC with limited liability and owned 51% of Xian Medical Chain
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"%"	per cent.

By Order of the Board
Hony Media Group
HAU Wai Man, Raymond
Company Secretary

Hong Kong, 8 April 2026

As at the date of this announcement, the Board comprises:

Mr. ZHAO John Huan[2] (Chairman), Mr. CHENG Wu[1] (CEO), Mr. YUEN Hoi Po[1] (President), Mr. YUEN Kin[3], Ms. WANG Song Song[3] and Ms. PAN Min[3]

[1] Executive director
[2] Non-executive director
[3] Independent non-executive director

In the case of inconsistency, the English text of this announcement shall prevail over the Chinese text.

** for identification purpose only*